Ana Garcia

Nov 11, 2024 | biorxiv.org | ANA GARCÍA |Ana Garcia |Antonio Trujillo |Maria Ferrer Aporta |German Vallejo Palma

AbstractPancreatic ductal adenocarcinoma (PDAC) is a devastating disease, marked by a survival rate of only 12%. Consequently, the exploration of novel therapeutic strategies becomes a critical clinical imperative. Among the genetic alterations contributing to PDAC, c-MYC overexpression arises due to upstream mutations, amplifications, and copy number alterations.

Feb 23, 2024 | mdpi.com | Ana Victoria García |Ana Garcia |Alejandra Fernández-Fernández |Elsa Villa-Fernández |Miguel García-Villarino

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Apr 19, 2023 | mdpi.com | Pedro Machado |Sara Pimenta |ANA GARCÍA |Ana Garcia |Tiago Sanches Nogueira

1. IntroductionLung malignancy accounts for more than 11% of global cancer incidence and is the major cause of cancer-related death, with an estimate of 1.8 million deaths in 2020 [1]. Surgical resection is the therapeutic option that offers the best prognosis to lung cancer patients, with overall survival rates of 74% and 62% at 3 and 5 years after surgery, respectively [2].